Compare Allegion PLC (ALLE) vs Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Allegion PLC vs Bio-Rad Laboratories, Inc. Class A Common Stock — how do they compare? Allegion PLC trades at $166.37 (market cap $14.32B), while Bio-Rad Laboratories, Inc. Class A Common Stock trades at $358.42 (market cap $9.43B). The key difference: Allegion PLC is the larger of the two by market cap, and Allegion PLC pays a 1.26% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| ALLE | BIO | |
|---|---|---|
Market Cap | $14.32B | $9.43B |
Sector | Industrials | Health |
52-Week High | $179.77 | $356.25 |
52-Week Low | $125.65 | $241.71 |
Enterprise Value | $16.03B | $9.18B |
Dividend Yield | 1.26% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Allegion (ALLE) trades at $165.53, down 2.02% today, near its consensus price target of $156. The stock shows bullish technical momentum with strong moving averages, though RSI levels suggest potential overbought conditions. Fundamentally, the company reported robust Q2 2026 results with EPS of $2.40 beating estimates and revenue growth of nearly 13% year-over-year, driven by strength in its Americas segment. It maintains solid profitability with a net income margin of 15.36% and ROE of 33.73%.
The outlook is positive, supported by raised full-year guidance and institutional buying, but risks include high valuation multiples and reliance on Americas market growth. Analyst sentiment is mixed with a 'Hold' consensus, indicating cautious optimism amid strong operational performance.
Bio-Rad Laboratories (BIO) trades at $351.10, down 0.97% on the day but maintaining strength near its 52-week high. The stock shows bullish technical momentum with strong moving average support and recently beat Q2 2026 earnings estimates with $2.62 EPS versus $1.75 expected. Fundamentals show improving profitability with 29.41% net margin in 2025, though revenue remains flat at $2.6 billion. Analyst consensus remains positive with 7 buy ratings and $350 price target.
BIO presents a mixed outlook with strong technical momentum and improving profitability offset by flat revenue growth and elevated valuation multiples. The stock's current price aligns with analyst consensus target, suggesting limited near-term upside. Key risks include academic research market softness and competitive pressures in life science instruments. Institutional ownership trends show continued confidence with recent position increases by major funds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Allegion PLC
Allegion is a global security products company with a portfolio of leading brands, such as Schlage, von Duprin, and LCN. The Ireland-domiciled company was created via a spinoff transaction from Ingersoll-Rand in December 2013. In fiscal 2021, Allegion generated 68% of sales in the United States. The company mainly competes with Swedish-based Assa Abloy AB and Switzerland-based Dormakaba.
Read more on ALLE →About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →
